Point72 Asset Management’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-254,862
Closed -$9.03M 2121
2024
Q1
$9.03M Sell
254,862
-53,738
-17% -$2.15M 0.02% 745
2023
Q4
$13.4M Sell
308,600
-596,526
-66% -$23.5M 0.03% 584
2023
Q3
$34.6M Buy
905,126
+904,626
+180,925% +$38.1M 0.1% 263
2023
Q2
$20.6K Buy
+500
New +$24.1K ﹤0.01% 1779
2021
Q2
Sell
-45,377
Closed -$3.13M 1057
2021
Q1
$3.13M Buy
+45,377
New +$3.07M 0.01% 663
2020
Q1
Sell
-237,554
Closed -$13.8M 913
2019
Q4
$13.8M Sell
237,554
-556,574
-70% -$33.1M 0.07% 326
2019
Q3
$47.7M Buy
794,128
+394,834
+99% +$23.5M 0.29% 93
2019
Q2
$22.3M Buy
399,294
+315,335
+376% +$16.2M 0.12% 222
2019
Q1
$4.68M Sell
83,959
-24,434
-23% -$1.24M 0.02% 566
2018
Q4
$4.89M Buy
+108,393
New +$5.95M 0.02% 562
2016
Q3
Sell
-516,800
Closed -$21.7M 781
2016
Q2
$20.6M Sell
516,800
-354,000
-41% -$12.7M 0.14% 177
2016
Q1
$29.3M Buy
870,800
+60,600
+7% +$1.89M 0.23% 120
2015
Q4
$27.5M Sell
810,200
-96,600
-11% -$3.02M 0.23% 123
2015
Q3
$27M Buy
+906,800
New +$28.4M 0.21% 142

Other funds holding IART

Point72 Asset Management's IART Position: Q2 2024 in Review

Point72 Asset Management sold out of Integra LifeSciences (IART) in Q2 2024, closing a stake of 254,862 shares — an estimated $9.03M sold.

Point72 Asset Management first reported a position in IART in Q3 2015 and held it in 14 quarters. The position peaked at $47.7M in Q3 2019. 238 funds tracked by Wall St. Rank hold IART as of Q2 2024.

  • Point72 Asset Management reported no remaining Integra LifeSciences position as of Q2 2024 after selling out during the quarter.
  • Point72 Asset Management sold 254,862 Integra LifeSciences shares in Q2 2024, an estimated $9.03M.
  • Point72 Asset Management first reported a position in Integra LifeSciences in Q3 2015 and held it in 14 quarters.
  • Point72 Asset Management's Integra LifeSciences position peaked at $47.7M in Q3 2019.
  • 238 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2024.

Based on Point72 Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.